| 加入桌面 | 手机版
免费发布信息网站
贸易服务免费平台
 
 
发布信息当前位置: 首页 » 供应 » 化工 » 化工中间体 » 医药中间体 » Cyproheptadine hydrochloride

Cyproheptadine hydrochloride

点击图片查看原图
品 牌: NANJIAN 
型 号: 969-33-5 
规 格: CP 
单 价: 240.00元/KG 
起 订: 1 KG 
供货总量: 1000 KG
发货期限: 自买家付款之日起 3 天内发货
所在地: 湖北 武汉市
有效期至: 长期有效
更新日期: 2014-10-31 17:02
浏览次数: 9
询价
公司基本资料信息
 
 
 
【Cyproheptadine hydrochloride】详细说明

Cyproheptadine hydrochloride
Product Name: Cyproheptadine hydrochloride
Synonyms: 1-methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidinehydrochloride;4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidinehydrochloride;4-(5h-dibenzo(a,d)cyclohepten-5-ylidene)-1-methyl-piperidinhydrochloride;cyproheptadienehydrochloride;nuran;periactinhydrochloride;periactinolhydrochloride;periactinsyrup
CAS: 969-33-5
Assay: 99%
Packing: 25kg/drum
MF: C21H22ClN
MW: 323.86
EINECS: 213-535-1
Appearance: White to light yellow crystalline powder

Use:

Anti coagulation, anti allergic drugs. Can be used for urticaria, eczema, allergic and contact dermatitis, skin itching and other allergic reactions. Urticaria, eczema, allergic and contact dermatitis, skin itching, rhinitis, asthma, migraine. Can also be used in Cushing's disease and acromegaly.

H1 receptor antagonist, than chlorpheniramine, promethazine, and had moderate resistance of 5 hydroxytryptamine and anticholinergic effects. In addition, clinical findings, new uses of cyproheptadine and treatment of mumps etc, studies show that the H1 antagonist cyproheptadine hydrochloride is 5 times more than chlorpheniramine maleate.

Banned in animal feed and drinking water substance

欢迎登陆化工在线,在线购物--维生素超市:http://www.wsscs.com/Refer?pid=fengxinwen$810

长江胆酸:http://www.meiliyl.com/Refer?pid=fengxinwen$800

狮子山:http://www.szsdope.com/Refer?pid=fengxinwen$819

乳液:http://www.szstuliao.com/Refer?pid=fengxinwen$820

表活时空:http://www.chrihua.com/Refer?pid=fengxinwen$818

咪唑中国:http://www.mizuoyl.com/Refer?pid=fengxinwen$815

0条 [查看全部]  【Cyproheptadine hydrochloride】相关评论
 
更多..本企业其它产品
 
更多..推荐产品

[ 供应搜索 ]  [ ]  [ 告诉好友 ]  [ 打印本文 ]  [ 关闭窗口 ]

 
站内信(0)     新对话(0)